\s=b\ The evaluation of any drug used to treat the comcon cold must necessarily be based on clinical observations. Bioflavonoids and ascorbic acid, singly and in combination, were evaluated in a study on almost 2,000 persons as to their efficacy, not by symptom alleviation but as to whether it would shorten the course of illness. The overwhelming impression gained from the study presented is the singular lack of effect in altering the course of the common cold by either the bioflavonoid or the
ascorbic acid.
The objective evaluation of a new form of treatment for the common cold has always proved difficult. Since the viruses causing it have thus far completely resisted all attempts at direct annihilation through the use of antibiotics, no bacteriological studies on the disap¬ pearance of the causative organism have proved fea¬ sible, nor have any other laboratory tests been found of great use in estimating the individual's rate of recov¬ ery. Therefore, the evaluation necessarily has been based essentially on clinical observations. Basically, treatment of the common cold has been limited to the relief of symptoms, the prevention of complications, and the general and specific supportive therapies that enable the body's own defense mech¬ anisms to overcome the disease. Because the illness is essentially self-limited, with serious complications de¬ veloping in only a small proportion of cases, any ther¬ apy that alleviates the patient's symptoms is called a cure until the test of time reduces it to the level of the other drugs that make the patient more comfort¬ able but do not appreciably affect the underlying cause of the disease. To postulate that a given drug has a specific effect upon the disease, therefore, it must be shown that it does more than relieve symptoms. It should shorten the course of the illness. Furthermore, since there are innumerable drugs that make the pa¬ tient more comfortable and alleviate symptoms, there¬ by creating subjective evidence that they are affecting the course of the cold, a cold cure should have an effect over and above the best of these relief medica¬ tions. Lastly, in view of the fact that the evaluation of effect is almost entirely clinical, and therefore sub¬ jective from the point of view of either the patient or the observer, the beneficial result of the drug should be demonstrable in a controlled experiment in which personal bias has been entirely eliminated.
In the past decade, much attention has been given to the treatment of colds by the use of drugs that would enhance the body tissue's resistance to invasion.
This has been at least in part behind the rationale for the use of such agents as antihistamines.1 Even more recently, the administration of ascorbic acid (vitamin C) has been advocated,2 both to raise the general resistance and on the theory that viral invasion is a function of capillary wall permeability that could be reduced by raising the ascorbic acid levels in the blood. On the basis of this theory, ascorbic acid has been added to a number of preparations used for the treatment of acute upper respiratory infections. The most recent approach to the problem has been an extension of this theory. It Since it is admitted that neither ascorbic acid nor the bioflavonoids have any in vitro effect on respira¬ tory viruses,7 such a study would have to be entirely clinical. It would be necessary to prove either that an appreciable number of colds were aborted in their early stages or that some or all of the symptoms were cleared up significantly earlier. The effect looked for would be more than a temporary alleviation of symp¬ toms and should therefore be demonstrable even in the presence of other medicaments given merely to that end. To avoid any possibility of observer bias, the trials should be made on a completely blind basis. Methodology Since the bioflavonoids were postulated as acting in conjunction with ascorbic acid, it was felt necessary to study the effect of the two substances both singly and in combination. An experimental design was used that would permit the evaluation of each compound inde¬ pendently and also would demonstrate any synergistic effect obtained. The trials were therefore conducted with the following four preparations: (1) 250 mg. of bioflavonoid (lemon bioflavonoid complex 497, Sunkist Growers) plus 50 mg. of ascorbic acid; (2) 250 mg. of bioflavonoid; ( 3 ) 50 mg. of ascorbic acid; and (4) placebo.
The subjects were divided into four groups, each of which was given one of these preparations four times a day. In order to demonstrate that any effect ob-served was more than that obtainable through stand¬ ard palliative practice, every patient received a prep¬ aration containing 325 mg. of salicylamide, 195 mg. of acetophenetidin, 65 mg. of caffeine, and 50 mg. of thonzylamine hydrochloride. This was done so that a patient not receiving ascorbic acid or bioflavonoid or a combination was actually receiving medication, which, in addition, acted as a control. Use of these four preparations enables one, by means of a square experimental design, to simulta¬ neously compare the effect of two drugs, both sep¬ arately and together, and yet to use all the patients in each of the comparisons. In figure 1 ascorbic acid (A in fig. 1 ) could be evaluated by comparing the upper two boxes and that of bioflavo¬ noid (B in fig. 1 ) could be evaluated by comparing the two left-hand ones, but this would utilize only half the patients for each evaluation. If, however, the patients in the left-hand side of the square are com¬ pared with those in the right-hand half, the effect of ascorbic acid will be demonstrated using all the pa¬ tients, since the two halves represent the same distri¬ bution except for the presence or absence of this factor. The patients indicated in the lower box of each half also receive bioflavonoid, but, since they are about the same proportion of the total, the effect of the latter will cancel out unless a marked synergism is present. The difference produced by bioflavonoid, irrespective of ascorbic acid, can be shown similarly by comparing the upper and lower halves.
The amount of synergism or antagonism can be evalu¬ ated by determining whether the difference between 00 (placebo) and AB is significantly greater or less than the sum of the difference between 00 and AO plus OO and OB.
The trials were conducted on subjects reporting to several outpatient industrial clinics under the super¬ vision of the physicians conducting the study. A num- ber of college, seminary, and private patients of one of the authors were also included. Medicaments sup¬ plied to these physicians were identified only by num¬ ber, so that neither they nor the patients were aware of what was being given. Furthermore, in order to re¬ duce the possibility of the clinical judgments being influenced by continued association of better results with one of the preparations, each of them was sup¬ plied under two numbers, making eight test groups in all to which the patients were assigned in rotation. Because it was not feasible to reexamine the sub¬ jects daily, a single checkup after three days was de¬ cided on. It was felt that, if colds were aborted to any appreciable degree by one or both of the drugs, the number of cures after three days should be appreci¬ ably higher than in the controls. At the same time, while some alleviation of symptoms was expected in all groups, the proportion should be materially in¬ creased in any group receiving an effective therapeu¬ tic agent in addition to the palliative medicament. The three-day limit was selected because, with a longer interval, too many cases might resolve spon¬ taneously, while a shorter time would not afford a chance for disappearance of symptoms even under effective therapy. Since the dispensaries were in op¬ eration from Monday through Friday, only those cases first seen on Monday, Tuesday, and Friday were in¬ cluded in the study, in order to permit a return at the proper time.
Patients coming to the dispensaries or private of¬ fices on those days were first examined. If a diagnosis of an acute upper respiratory infection was made, patients were admitted to the study and assigned to one of the eight test groups in sequence. Their symp¬ toms, physical findings, and other pertinent data were then recorded on a special printed form, which was precoded for machine punching and tabulation. The patient was given sufficient medicament to provide four doses a day for three days and instructed to re¬ port back at the end of that time. To simplify com¬ pounding and dispensing the medicaments, the in¬ gredients that varied from group to group were put into one capsule, while those given to all groups were put in another. Cough medicine and nasal decongestants were also dispensed if indicated and were re¬ corded on the form. In the case of the industrial patient, when secondary bacterial infection appeared to be developing, he was recommended to his per¬ sonal physician.
Symptoms to be recorded were limited to eight considered most characteristic of the common cold:
running nose, sneezing, hoarseness, cough, malaise, headache, postnasal drip, and sore throat. Only their presence or absence at the initial visit was noted, to avoid the difficulty of grading their severity. The time since the onset of the first symptoms was also recorded, as was the patient's temperature at the initial visit. The notation of physical findings was also limited to those associated with acute upper respiratory infec¬ At the examination on the third day, the presence or absence of the same symptoms was again recorded, and the physical findings were graded as before. The over-all change in the patient was evaluated, both subjectively and objectively, as worse, no change, im¬ proved, or cured. A note was made on whether the patient had taken all his pills and whether he had remained at work and on the number of days lost, if any. All these entries could be recorded on the study form simply by circling the appropriate finding under each heading.
Analysis of Results
Almost 2,000 individuals with acute upper respira¬ tory infections between January and May, 1956, were used in the study. A small number were dropped for failure to report back on the third day, and a few study forms were not completely filled out, but the over 1,900 observations reported under all headings were a more than adequate sample to demonstrate any significant differences that might be produced by the drugs. The coded findings on each case were punched on IBM cards, which were then sorted by test group. These were tabulated for each observa¬ tion and the distributions percentaged or converted to means. ( Where appreciable differences in percentages or means were found, tests for statistical significance were made, using a chi-square test for percentage variations and a t-test for evaluating differences in means. Because of the many observations compared, differences were not considered significant unless the chance probability was 1% or less. ) Table 1 shows the distribution of the eight treat¬ ment groups by age and sex. The small differences noted were all accounted for by random sampling variation, and there were no statistically significant differences. The comparability of mean number of colds per year shown in this table indicates that the groups were also random with regard to patients' susceptibility to colds. These eight groups were com- bined into two groups representing the patients re¬ ceiving and not receiving bioflavonoids, and also the two different groups that did and did not receive ascorbic acid. The following tabulations are presented for all these combinations. Table 2 gives further evidence of the statistical comparability of the groups. The percentage of patients with pharyngotonsillitis and tracheobronchitis was not significantly different from group to group. Roughly the same proportion of patients required additional medicaments in each group, including antibiotics, nasal decongestants, and cough medicine, in addition to the medicaments under test, and none of these additional medicaments was given in a high enough percentage of cases to have seriously influenced the results of the study. The pro¬ portion of patients who did not take all their pills also did not vary significantly between groups. Cross tabu¬ lations (not shown) of all these factors against sub¬ jective and objective improvement indicated that the elimination of patients who received supplementary medicaments or did not take all their pills would not have appreciably affected the results of the study. Table 3 shows the effect of bioflavonoid and as¬ corbic acid on the improvement after three days, judged by both the patient and the clinician. The distributions with and without each of the drugs are almost identical, for both subjective and objective change, with absolutely no statistically significant dif¬ ferences demonstrable. This is graphically illustrated in figure 2 . The ameliorating effects of the two drugs on the patients' symptoms are evaluated in table 4.
It will be noted that on initial examination the per¬ centage of patients in each group having each symp¬ tom was strictly comparable. The number of patients having the symptoms at the end of three days was then tabulated, and the percentage decrease, based on the number originally reported, was calculated. In a few instances patients developed symptoms after the first visit, but these cases were canceled by others in which the symptoms disappeared, and the number in any event was too small to affect the statistical significance of the data. The difference in percentage decrease that might be attributable to drug effect is shown in the right-hand column. It clearly indicates that neither bioflavonoid nor ascorbic acid had more than a random effect on any of the symptoms of the patients.
The effect of the two drugs on nasal secretions is shown in table 5. Again the initial distributions are well within random limits. There is a noticeable drop in the percentage with mucoid secretions after three days, but this change is almost identical in the groups receiving and not receiving both bioflavonoid and as¬ corbic acid. There is an actual increase in the per- There was a uniform decrease in the amount of ob¬ struction in all groups, with no significant differences attributable to either of the drugs. In table 7, the amount and severity of the pharyn¬ gitis found is tabulated. Again there were no appreci¬ able differences in the distributions before therapy. There was a uniform decrease in the amount of phar¬ yngitis found after three days, with neither of the changes in distribution exhibiting more than random variation.
Although this study was designed for outpatient follow-up, it was felt that the disposition and lost time might shed some light on the function of the drugs. Table 8 indicates that there has been no effect on these factors. The proportion of subjects sent home from work on the first visit could not be attributed to drug effect, but the uniformity noted is another indication of the comparability of the groups with regard to severity of infection. The percentage sent home on a subsequent visit might be an inverse index of the efficacy of the medication, but again there was no appreciable variation. The mean number of days lost, which would be a function of both initial se¬ verity and drug effectiveness, also showed no sta¬ tistically significant differences.
On the theory that the effect of the drugs on capil¬ lary permeability might only be beneficial if they were given at the start of the illness, the data on patients treated within 24 hours of the development of symp¬ toms were sorted out and tabulated in table 9 for subjective and objective change after three days. Not only was no difference of effect noticed between the patients who did or did not receive either of the drugs, but the distribution by improvement did not differ significantly from that in the total number of patients, regardless of the number of days since on¬ set (table 3) .
Since the study was conducted in the dispensaries or offices under the supervision of three different physicians, it was considered advisable to evaluate some of the findings in each separately, to determine whether any had achieved significantly different re¬ sults than the others. This analysis for subjective change is shown in ta,ble 10. It will be noted that the distributions are noticeably different under the three auspices, with statistical significance at well beyond the 0.1% level between all of them. This is due either to variation among the institutions in the standards for determining the subjective changes or to factors in the composition of the groups or the collateral treatment, such as the inclusion of students and pri¬ vate patients. The locality and the infecting organism may also be a factor. It is interesting, also, that all areas of the United States were included in this study.
That it was not due to either bioflavonoid or ascorbic acid is evident from the fact that, despite wide vari¬ ation in distribution between institutional groups, there were no statistically significant differences due to the two drugs within any of the groups. The per¬ centage differences noted, particularly in the Pratt-Whitney group, are still within the limits of random variation for a group of this size.
When the study had been running for several months, a preliminary check on the cases already re¬ ported indicated no effect from the bioflavonoids. On the off chance that another compound might prove more effective, the medicaments were switched from lemon to orange flavonoid and the study continued.
The difference in effect of these two products on sub¬ jective and objective change is shown in table 11.
While the lack of effect is more evident in the lemon flavonoid group, the differences noted between the patients receiving and not receiving orange flavonoid did not reach statistical significance and can be com¬ pletely accounted for by chance variation. It will be noted that the results with orange flavonoid were significantly worse than those obtained with the lemon flavonoid controls. This difference is probably due to a change in the severity of respiratory disease in the later months when the orange compound was being evaluated and emphasizes the ' importance of simul¬ taneous controls as were used in this study. 
Comment
The overwhelming impression gained from all these data is the singular lack of effect produced by either the bioflavonoid or the ascorbic acid. If any real clini¬ cal response were produced by either of these drugs in even an appreciable minority of the patients treated with them, significant statistical differences should have been evident in at least some of the factors ob¬ served. This is particularly so because of the large sample size and the exact comparability of the test groups for all observed factors at the start. The lack of difference cannot be attributed to the limitation to a single reobservation. In any drug in¬ fluencing the course of an acute self-limited disease, some changes must be noticeable in at least some of the symptoms after three days or else the effect is so negligible that it can be completely discounted. The procedure used did not evaluate the effectiveness of either of the drugs in preventing secondary bacterial infections and other complications, for which a mini¬ mum of a second reexamination after one week would have been necessary, because it had been designed to test the claim that the bioflavonoids, in conjunction with ascorbic acid, aborted or cured the common cold.
Neither did it evaluate the use of these vitamins in prophylaxis against the common cold. The study cannot be invalidated on the basis of too high a percentage of placebo reactors. It is well known that the majority of common colds are alleviated to some extent by the administration of any symptomatic therapy, and the improvement noted in the over 1, 900 cases is about what one would expect after three days of such therapy. For the claims for the drugs being tested to be substantiated, there would have to have been present an effect over and above that found for the entire group, and this difference was completely lacking.
It will be noted that no analyses were performed on the individual drug groups to evaluate synergism or antagonism. In the absence of any differences be¬ tween the combined groups specific for bioflavonoid and for ascorbic acid (see section on methodology), it seemed necessary to look for such effects. It is sta¬ tistically possible for two drugs to both have a bene¬ ficial effect but to be completely antagonistic and cancel each other, in which case the analysis used would yield a false-negative result. An unusual effect of this kind, however, would be immediately apparent by simple inspection of the data at the time the groups were combined, and it was not noted. Thus far there is no convincing evidence that bio¬ flavonoids or ascorbic acid can alleviate a cold when used alone or in combination with other therapies, and our evidence confirms the conviction that bioflavonoids or ascorbic acid are without specific effect in such con¬ ditions. Although some might argue that much higher doses of either bioflavonoids or ascorbic acid are nec¬ essary to demonstrate a curative effect, we empha¬ size that the patients in this study received 200 mg. of ascorbic acid and 1 gm. of bioflavonoid per day, levels generally considered adequate to affect the capillary permeability. Since the usefulness of these compounds in reducing capillary fragility has gener-ally been applied to long-standing conditions, there is no reason to believe that massive doses would achieve the rapid effect necessary in conditions as acute as a cold.
Summary
The effect of 1 gm. of bioflavonoid and/or 200 mg. of ascorbic acid administered daily in aborting or curing the common cold was tested in a controlled double-blind trial on over 1,900 subjects. The medi¬ caments were given, either singly or in combination, in addition to the usual treatment used to alleviate symptoms. No appreciable effects were observed after three days on subjective or objective improvement; on disappearance of running nose, sneezing, cough, hoarseness, malaise, headache, postnasal drip, or sore throat; on decrease in nasal secretions or obstruction or pharyngitis; or in time lost from work. In our opinion neither of these drugs in the dosage given has any significant effect in altering the course of the common cold.
1740 Broadway (Dr. Tebrock).
